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Abstract 
Purpose: Public engagement in health technology assessment (HTA) is increasingly 
considered crucial for good decision-making. Determining the “right” type of engagement 
activity is key in achieving the appropriate consideration of public values. Little is known 
about the factors that determine how HTA organizations decide on their method of public 
engagement, and there are a number of possible factors that might shape these decisions.  
This paper seeks to understand the potential drivers of public engagement choice from an 
organizational perspective. 
Design/Methodology/: The published HTA literature is reviewed alongside existing 
frameworks of public engagement in order to elucidate key factors influencing the choice of 
public engagement process undertaken by HTA organizations. A conceptual framework is 
then developed to illustrate the factors identified from the literature that appear to 
influence public engagement choice.  
Findings: Determining the type of public engagement to be undertaken in HTA is based on 
multiple factors, some of which are not always explicitly acknowledged. These factors 
include: perceived complexity of the policymaking issue, perceived impact of the decision, 
transparency and opportunities for public involvement in governance, as well as time and 
resource constraints. The influence of these factors varies depending on the context, 
indicating that a one size fits all approach to public engagement may not be effective. 
Originality/value:  Awareness of the various factors that might influence the type of public 
engagement undertaken would enable decision-makers to reflect on their choices and be 
more accountable and transparent about their choice of engagement process in eliciting 
public values and preferences in a HTA organization. 
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Introduction  
Health technology assessment (HTA) is a multidisciplinary process, used by policy making 
bodies, to analyze and summarize information about medical, social, economic and ethical 
issues related to the use of a health technology (Banta 2003). Increasingly, public 
engagement has become an important component of this process. The term ‘public’, once 
mainly confined in this context to patients and consumer advocacy groups, is now 
understood to include ‘ordinary’ or ‘lay’ citizens who have not necessarily had contact with 
the relevant health services but have a ‘stake’ in the decisions made by policy makers by 
virtue of being members of the community (Mitton et al. 2009). There are a number of 
organisations worldwide that conduct or commission assessments of health technologies. 
These organisations (referred to collectively as HTA organisations—HTAOs) usually conduct 
some form of public engagement to guide their decisions about health technologies or to 
guide the recommendations they make to policy makers by whom they have been 
commissioned (Hailey and Nordwall 2006). Public engagement is seen as a means to 
increase the legitimacy of this advice and/or decision-making and ensure that decisions 
made are relevant to stakeholders, transparent, and responsive to relevant social values 
(Facey et al. 2010; Littlejohns et al. 2012; Nilsen et al. 2006).  
The phrase ‘public engagement’ is used broadly in this context, to encompass a range of 
participative techniques aimed at supporting dialogue about values between groups and/or 
individuals—usually between decision-makers and interested parties outside the decision-
making process. It extends from basic information provision to more complex methods of 
participatory deliberation and collaboration such as citizens’ juries, consensus conferences 
and planning cells (Rowe and Frewer 2005). Many frameworks have conceptualized public 
engagement practices in public policy processes (Arnstein 2011; Harrison and Mort 1998; 
Head 2007; International Association for Public Participation (IAP2) 1999; Tritter and 
McCallum 2006).  Most describe a continuum of engagement techniques characterized by 
increasing citizen influence, commitment and/or participation. Ideally, public engagement is 
underpinned by the principle that those affected by a decision have a right to be involved in 
the decision-making process.  Often however the actual practice of engagement is perceived 
as a tokenistic effort on the part of decision-makers, or as a reactive process (House of 
Commons Public Administration Select Committee 2013), driven by public dissatisfaction 
about an impending decision.  It therefore tends to follow that the greater the perception of 
dissatisfaction or conflict, the greater the ‘push’ for public engagement involving greater 
participation.   
Given that there are a range of public engagement techniques, and that they arise from a 
variety of motivations, it is important to be able to understand how and why they evolve as 
they do. However, it remains unclear why HTAOs might choose one engagement type over 
another. Some authors have suggested that differences can be explained by the intended 
purpose of the engagement and perceived effectiveness of the type of engagement in 
achieving this purpose (Chafe et al. 2009).Others have argued that the choice of 
engagement type will vary depending upon the influence of other contextual factors, such 
as the nature and complexity of the technology, stakeholder interests, the potential impact 
of the technology on the population or budget, as well as the ‘public’ being asked (Canadian 
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Institutes of Health Research (CIHR) 2012; Degeling et al. 2015; Gauvin et al. 2010b; HIQA 
2014). 
The question of which ‘public’ to include in public policymaking is a contentious issue in HTA 
and in health more generally (Martin 2012). In a recent review looking at public deliberation 
in public health and health policy research it was found that researchers use different 
‘publics’ for different purposes (Degeling, Carter, & Rychetnik 2015). Patients, advocates or 
consumers, otherwise known as partisan groups, are often engaged as witnesses or experts 
on a specific matter whereas lay, non-partisan or disinterested citizens are more frequently 
asked to be involved in broader policy making decisions. This distinction between partisan 
and non-partisan participants is often unclear in reporting on public engagement (Martin 
2012) (Degeling, Carter, & Rychetnik 2015) While some authors (Sarrami-Foroushani et al. 
2014b) consider the question of ‘which public’ to be a factor in determining the type of 
engagement chosen by HTA agencies, the definition of ‘publics’ remains contentious. For 
this reason, we have chosen to use the term ‘public/s’ to refer to patients, consumers and 
advocacy groups, as well as citizens representing broader societal interests and use the 
terms ‘targeted’ and ‘untargeted’ (Rowe & Frewer 2005) (Sarrami-Foroushani, Travaglia, 
Debono, & Braithwaite 2014b) to indicate how individuals are selected for public 
engagement.  
Framing of the research question 
Our aim in conducting this review was to understand and theorize potential drivers behind 
the choice of public engagement type by HTAOs. We were particularly interested in 
understanding why, for some HTAOs, there appears to be a reluctance to undertake public 
engagement approaches that have been proposed by HTA stakeholder groups (Lopes et al 
2015) or carried out by researchers in the field to address health technology policy 
questions. Recent research in this area indicates that members of the public want public 
engagement in decisions where uncertainties are present in the evidence, transparency is 
lacking and where ‘value’ (trade-offs between costs and benefits) is central to the HTA 
decision (Wortley et al 2016a).    
As such the aim of this paper is not to describe how public engagement is conducted, or to 
determine how it should conducted, but rather provide a framework that HTAOs might use 
to examine where and when they might use public engagement and what other factors they 
might consider, including the tensions and trade-offs inherent in their choice of method 
(Sarrami-Foroushani et al. 2014a). This should not only facilitate HTAO’s internal decision-
making process, but also enable them to be explicit about how they have reached their 
decisions, thereby opening dialogue, building trust and facilitating negotiation as to what 
modes of public engagement are desirable and possible. This may be particularly helpful for 
HTAOs in low or middle income countries where time and resources are lacking (Danko and 
Petrova 2014) yet public engagement in still desired.  
Methods 
The approach we used was based on interpretative hermeneutic analysis (Smith et al. 2009). 
This approach allows theory development through an iterative, and interpretive approach, 
acknowledging the lens of the researcher within the analytic process – as in this case all 
authors have worked in association with HTAOs and/or on projects relating to HTA decision-
making.  
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Data are identified from a range of sources using expansive searches with constant review 
and reflection.  While the strength of this method is in its interpretive and emergent nature, 
this method risks criticism based on the perceived lack of a systematic, reproducible and 
transparent process. We attempted to reduce this by following the methodologies 
described by others working in this field of theory generation, evidence synthesis and health 
(Pawson 2006, Finfgeld-Connett and Johnson 2013) and as outlined below. 
As our perspective was from an organizational viewpoint, we used the Context-
Management-Mechanism-Outcome (CIMO) Framework to refine the question (Denyer and 
Tranfield 2009) (Table 1).  
Table 1: Question as defined by the CIMO Framework (Denyer and Tranfield 2009) 
Context Health Technology Assessment Organisations 
Intervention Public engagement  
Mechanisms Factors that determine choice of public engagement method - to be explored  
Outcomes Public engagement approaches undertaken 
 
Using the approach above we first identified (i) existing frameworks on public engagement. 
From these frameworks we undertook to identify (ii) public engagement frameworks from 
HTAOs or similar health organisations (iii) published literature examining factors of 
importance in HTA or evidence-based policy decision-making.  
To identify relevant literature we searched the following databases: MEDLINE, MEDLINE In-
Process & Other Non-Indexed Citations, EMBASE, Sociofile and DARE and HTA (CRD) from 
Jan 1999 to March 2014. The choice of time period reflects the relatively recent emergence 
of public engagement themes in HTA discourse (Banta and Jonsson 2009). The construction 
of the search strategy was an iterative and divergent process (Booth et al. 2013), informed 
by our analysis and interpretation consistent with a hermeneutic approach (Boell and Cecez-
Kecmanovic 2014). Text words related to public engagement and participation [e.g. 
deliberation, patient*, public] were combined with Medical Subject Heading [MeSH) terms 
relating to HTA [e.g. ‘evidence based medicine’, ‘biomedical technology assessment’, etc.] 
and MESH terms encompassing health policy decision making. Google scholar, websites of 
international HTAOs, and the Health Technology Assessment International (HTAi) interest 
subgroup on Patient and Citizen Involvement in HTA Interest Sub-Group were also searched 
using a pearl-growing method (Ramer 2005) and text words from the search. Reference lists 
of all included studies were also searched for potentially relevant studies. Searching ceased 
once it was determined that no new concepts were being identified in the literature 
(Finfgeld-Connett and Johnson 2013). 
Key concepts and findings were extracted from the relevant studies, along with author 
information, purpose of the article, perspective and evidence source.  These data were 
placed in a table, with similar concepts grouped together. The data were then interpreted, 
discussed between two of the authors before being further reordered and revised following 
reflection among all authors.  Table 2 outlines the key concepts and inferences made from 
the studies.
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Table 2: Key concepts from the literature on factors appearing to influence the choice of public engagement: decision-makers’ perspectives 
 
Frameworks of 
public 
engagement 
 
Frameworks of public engagement in 
settings Health/HTAOs 
 
Published studies reporting on factors of importance in HTA or evidence-
based policy decision-making. 
 
Proposed term for 
framework and 
implications for choice 
External Factors 
‘Complexity of the 
information to be 
understood by 
participants’ 
(Robinson 2003) 
Complexity of the topic ‘dependent on 
the research questions, quality and 
quantity of evidence’ 
HIQA (2014)   
Complexity of the issue  
(CIHR 2012) 
Purpose of the HTA  
HIQA (2014)   
Purpose of the decision-making (Dobrow, 2004) 
Characteristics of technology (Gauvin 2010) 
Quality and uncertainty of evidence (Guindo 2012) 
Clinical effectiveness (Stafinski 2011) 
Cost effectiveness (Stafinski 2011) 
Perceived complexity of 
policymaking issue –  
higher level of 
participation/involvement 
as complexity increases 
(Robinson 2002, HIQA 
2014, CIHR 2012) 
Inherent risk in 
situation (e.g. 
potential for social 
and environmental 
impacts’ 
(Robinson 2003) 
 
Public impact of 
the topic (IAP2) 
Sensitivity of the topic  
‘related to public and patient interest 
in disease, technology, historical 
context and whether opinions are 
divided’ 
HIQA (2014) 
Impact or level of public interest, 
conflict, or controversy 
 (CIHR 2012) 
 
 
Demographic and epidemiologic characteristics of a disease/severity and 
burden of disease (Dobrow, 2004) (Stafinski 2011) 
Impact of the disease targeted by intervention (Guindo 2012) 
Health outcomes and type of health benefit (Guindo 2012) 
The interests of stakeholders involved (Gauvin 2010) 
Political factors. (Dobrow, 2004), (Guindo 2012) 
Availability of alternatives (Stafinski 2011) 
Cost to society (budget impact) (Stafinski 2011) 
Cost to patient (Guindo 2012) 
Patient preferences (Stafinski 2011) 
Perceived impact of 
decisions on 
stakeholders–  
higher level of 
participation/involvement 
as impact increases 
(Robinson 2002, HIQA 
2014, CIHR 2012) 
Internal Factors 
 Timeframe of the HTA  
HIQA (2014) 
Internal capacity (CIHR 2012)  
Cost implications (CIHR 2012) 
 
Timeliness  (Stafinski 2011) 
 
Time and resources- 
More time and costs 
available able to have 
higher level of 
participation/involvement 
(HIQA 2014, CIHR 2012) 
 Need for input from specific 
stakeholders HIQA (2014) 
 
 
Role of participants in a decision-making process (Dobrow, 2004) 
Process employed to arrive at a decision (Dobrow, 2004) 
The agency's institutional context (Gauvin 2010) (Guindo 2012) 
The HTA community's ideas regarding health technologies, HTA, and public 
involvement (Gauvin 2010) 
 
Transparency and 
opportunities for public 
involvement in 
governance 
 
6 
 
Existing frameworks used to guide choice of public engagement type  
We identified two main frameworks that are used, referred to, and/or adapted by those 
describing and evaluating public engagement  HTA. The Rowe and Frewer framework (2005) 
(Rowe & Frewer 2005) describes three broad types of engagement: communication, 
consultation, and participation. In the framework, the three types are differentiated based 
on the direction of flow of information between participants and the ‘sponsor’ (in this case, 
the HTAO). Subtypes of engagement methods are based on other factors, such as selection 
of participants, facilitation of participation and framing of responses with techniques for 
each subtype listed. 
Several surveys and reviews have been conducted to determine the extent and type of 
public engagement currently practiced by HTAOs (Hailey & Nordwall 2006; Menon and 
Stafinski 2011b; Whitty 2013). The most recent of these (Whitty 2013) applied Rowe and 
Frewer’s (Rowe & Frewer 2005) typology, and found engagement techniques based on 
communication, typically provision of information on a website, and consultation (focus 
groups and discussion documents) were the mainstay of HTA public engagement strategies. 
Consultation was undertaken in either an untargeted manner or by using a targeted/ 
partisan selection of particular participants by HTAOs. Only a small proportion of agencies 
undertook participatory approaches (Whitty 2013), however there appears to be a growing 
interest in these methods (HIQA 2014; Menon & Stafinski 2011b; Mitton, Smith, Peacock, 
Evoy, & Abelson 2009) – particularly deliberative methods such as consensus panels and 
citizens’ juries (Bombard et al. 2011; Facey, Boivin, Gracia, Hansen, Lo Scalzo, Mossman, & 
Single 2010; Watt et al. 2012). 
Apart from the assessment framework of Rowe and Frewer (Rowe & Frewer 2005), 
discussed above, another frequently used and adapted framework for evaluating 
engagement is the ‘Spectrum of Public Engagement’ developed by the International 
Association for Public Participation (IAP2) (International Association for Public Participation 
(IAP2) 1999). This framework outlines the different types of engagement (inform, consult, 
involve, collaborate, empower) that organizations can undertake to engage 
stakeholders/communities. The further to the right on the Spectrum, the greater the 
influence the community has on decision-making.  The IAP2 Spectrum presents a continuum 
of levels of engagement where the most appropriate engagement format is selected 
depending on the topic (International Association for Public Participation (IAP2) 1999). One 
of the limitations of the IAP2 Spectrum is the lack of guidance given to direct this selection. 
The selection decision, according to Hardy (2015) can be viewed as a process of negotiation 
between the organization and community. This may be influenced by the culture and 
structure of the organization, as well as internal pressures, for example time and financial 
costs, and issues relating to the nature and complexity of the actual topic (Canadian 
Institutes of Health Research (CIHR) 2012;Corporate Consultation Secretariat 2000). The 
IAP2 Spectrum is currently under review because of these debates in the public engagement 
field. Some authors (Robinson 2003) (Praxis group 2012) however have adapted the 
Spectrum to make explicit some of these factors in driving selection of engagement, namely 
the inherent risk (impact) and complexity of information which needs to be understood by 
the participants. This can also be applied to the field of HTA which will be discussed below.  
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Analysis of factors 
From analysis of the data, we propose that there are four main drivers that influence the 
choice of public engagement process undertaken by HTAOs (Table 2). These relate to both 
content of the HTA itself; which we refer to as the ‘complexity’ and ‘impact’ of a topic – 
external to the organisation -  as well as other internal factors associated with the HTAO. 
These internal factors include the time and resources available to the HTAO and the existent 
organizational culture, structure and processes of the HTAO - labelled ‘transparency and 
opportunity for public involvement in governance’. These latter factors are rarely made 
explicit in public engagement frameworks, yet are just as influential in determining when 
and how engagement in undertaken (Gauvin et al. 2010a). 
Factors influencing the choice of public engagement type undertaken by HTAOs: 
 Perceived complexity of the policymaking issue 
Existing public engagement frameworks suggest that as a decision becomes more complex, 
a different type of engagement may be sought (Canadian Institutes of Health Research 
(CIHR) 2012; International Association for Public Participation (IAP2) 1999; Robinson 2003). 
While some could argue that in an HTA the content, and the associated deliberations, are 
always complex, the literature appears to indicate that there is a spectrum of complexity. 
Where a particular HTA is seen to sit on this spectrum is often driven by factors such as the 
characteristics of the technology under review, the research question, and the type, 
quantity and quality of the evidence available (HIQA 2014). For example, medical tests 
(screening, diagnostic tests, co-dependent technologies) are often considered complex due 
to the type of evidence available, the quality of this evidence, and the subsequent 
assumptions that need to be made when transforming this evidence for use in an economic 
model assessing final health outcomes (Merlin et al. 2013). This is in contrast to a situation 
where a technology is already considered standard practice and/or where there is a large 
body of good quality evidence showing a consistent effect. 
According to Plsek and Greenhalgh ( 2001) complexity is also intertwined with issues around 
uncertainty. It is uncertainty that has proven to be one of the greatest challenges for 
decision makers in HTA, particularly with the current pace of innovation and the rise of 
personalized medicine for which trials are often small and evidence of safety and efficacy 
often uncertain (Grutters et al. 2015). From a policy-maker’s perspective, decisions often 
need to be made regardless of the level of evidentiary certainty. In such situations of 
uncertainty, opportunities are seen to exist for other sources of evidence, such as public 
perspectives, values and preferences, to influence and legitimize processes (Sharma et al. 
2015). For complex decisions, public engagement therefore needs to facilitate 
understanding - often through the consultation and/or deliberation of the uncertainties 
inherent in the assessment. 
Perceived impact of decisions on stakeholders 
Perceived impact relates to the size of the perceived effect of a decision on the community 
that it will impact, and is often framed in terms of the ‘sensitivity’ of a topic (HIQA 2014)  to 
the interests of the stakeholders involved (Gauvin, Abelson, Giacomini, Eyles, & Lavis 
2010b). The studies we reviewed suggest that characteristics of both the disease and the 
technology can determine the perceived impact of a decision (Dobrow et al. 2004;Gauvin, 
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Abelson, Giacomini, Eyles, & Lavis 2010b;Stafinski et al. 2011b). This includes the number of 
people in the intended population to be impacted by the technology, the characteristics of 
the population (e.g. age), the perceived benefit of the technology, the availability of other 
diagnostic or therapeutic options, and the cost of the technology – both to the individual 
and society (Dobrow, Goel, & Upshur 2004;Stafinski et al. 2011a). In a recent report from 
the Ontario Health Technology Advisory Committee (OHTAC), it is recommended that public 
engagement should be “proportional to the nature and purpose of the technology, size and 
demographics of the targeted patient population, and disease incidence and prevalence” 
(OHTAC Public Engagement Subcommittee 2015, p.15) i.e that more participative 
approaches are needed for high impact topics.  
High impact topics are those most likely to require trade-offs and/or about which 
stakeholders have strongly held beliefs. Population screening is one example of a high 
impact HTA (Dobrow, Goel, & Upshur 2004;HIQA 2014):  potentially large numbers of 
individuals are involved and there is complex trade-off of costs, risks and benefits (Rychetnik 
et al. 2013). Some pharmaceuticals also exhibit these characteristics; trastuzumab for 
recurrent/ metastatic breast cancer, ivacaftor for cystic fibrosis (O’Sullivan, 2013) and 
ipilimumab for advanced melanoma (PBAC 2012) have all demonstrated efficacy and 
potential for substantial health gain but are high cost. In such circumstances the literature 
suggests that deliberative or participatory approaches are most appropriate to allow the 
public’s perspectives, values and concerns to be fully explored and understood when topics 
are sensitive (Watt, Hiller, Braunack-Mayer, Moss, Buchan, Wale, Riitano, Hodgetts, Street, 
& Elshaug 2012;Whitty et al. 2014) thereby reducing potential conflict around a decision 
(Rychetnik, Carter, Abelson, Thornton, Barratt, Entwistle, Mackenzie, Salkeld, & Glasziou 
2013).  
Transparency and opportunities for public involvement in governance  
This factor relates to the environment in which a decision is made, and captures the 
organizational culture, processes (transparency) and structure of the HTAO. For many 
HTAOs, fulfillment of the opportunity for governance involves simply giving a public 
representative –typically a consumer advocate - a ‘seat’ or voice at the decision making 
table. Both Whitty (2013) and Menon & Stafinski (2011a) found that individual citizens were 
more likely than patients or consumer representatives to be included in development of 
HTA processes (for example the Citizens Council at National Institute of Health and Care 
Excellence - NICE).  The reverse was true for processes around specific technology decisions 
where patients or partisan groups were consulted and engaged more frequently. It has been 
suggested that this may be because partisan groups can provide an efficient and publicly 
visible route to consider issues (Kahane et al. 2013). Many countries have undertaken 
significant training and education activities to support and strengthen patient and patient 
advocate involvement in HTAs (Consumers Health Forum 2013;EUPATI 2014;pan-Canadian 
Oncology Drug Review (pCODR) 2013;Patient Access to Cancer care Excellence (PACE) 2014). 
These internal processes often also serve as promoters of transparency and demonstrate 
commitment to other values required for effective public engagement (HTAi 2014). Other 
studies have also noted the importance of the role of stakeholders in internal organizational 
processes (Martin 2008), based on the idea that stronger internal processes will enable 
individuals’ greater influence in decision-making (International Association for Public 
Participation (IAP2) 1999) (Gauvin et al. 2014). Clark and Weale (2012) also acknowledge the 
importance of these types of process values in health care decision-making. However rather 
than enabling influence, Clarke and Weale (2012) see participation and transparency as a 
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way of promoting greater trust and confidence in the system and ultimately legitimacy in 
the decision  
Time and resources (financial and knowledge) 
Time constraints are often not explicitly acknowledged as a factor in choice of method of 
public engagement, but this is often implicitly understood (Gauvin, Abelson, & Lavis 2014) 
(Irvin and Stansbury 2004). Indeed, some recent publications acknowledge the impact of the 
time on public engagement choice (e.g. OHTAC Public Engagement Subcommittee 2015). A 
common criticism of the HTA process is the time it takes to produce reports and to make 
policy decisions (Drummond et al. 2008;McGregor 2006).  It has been estimated that two to 
three weeks (HIQA 2014) need to be added to completion time each time a decision making 
committee meets. Public engagement is seen to substantially increase the time required 
(Ford et al. 2012) and many view public participation in the HTA process as a trade-off 
between engagement and timeliness (Stafinski, Menon, McCabe, & Philippon 2011b).  
Public engagement also involves a financial cost to the HTAO. There is little in the literature 
on this aspect of public engagement (Burns et al. 2014;Pizzo et al. 2015), but it is highly 
likely that cost would be a factor in decision-making about methods of public engagement. 
This is reflected in the fact that deliberative methods such as citizens’ juries, which involve 
substantial costs, (Watt, et al 2012) are often reserved for complex or substantive issues 
(Abelson et al. 2003b). The Agency for Healthcare Research and Quality’s (AHRQ) Effective 
Health Care Program (EHCP) (Carman KL et al. 2013a), for example, recently undertook a 
randomized controlled trial where the decisions of four groups using deliberative methods 
(Brief Citizens’ Deliberation, community deliberation, Online Deliberative Polling®, Citizens’ 
Panel) were compared to those of a control group. As well as reporting effectiveness 
outcomes, the costs of directly holding each deliberative method was reported.  Costs 
ranged from US$45,000-$82,800 depending on the number of engagement groups and 
methods. Similar findings were reported in an Australian study which reported costs for 
deliberative strategies between AUD$90 500-$93 040 (Watt, et al 2012). While these costs 
are dwarfed by the public money that potentially will be expended on a new technology it 
doesn’t mean that the HTAO has adequate resources to commit to pursue these activities. 
Most HTAOs also undertake public engagement activities themselves, rather than engaging 
expert external groups (Whitty 2013). The type of engagement will therefore be dictated by 
skills, knowledge and preferences of the HTAO (House of Commons Public Administration 
Select Committee 2013). For example, a HTAO may be more likely to use focus groups 
rather than a quantitative preference assessment method, such as a discrete choice 
experiment, simply because of familiarity with the methodology. Such a situation is 
suggested in the study by Whitty (2013) which indicated that use of online consultation 
documents is by far the most prevalent approach to public engagement undertaken by 
HTAOs. 
Development of a framework 
Using the previously described literature on theoretical frameworks of public engagement 
(International Association for Public Participation (IAP2) 1999; Robinson 2003;Rowe & 
Frewer 2005) and the four factors that we have identified that appear to influence the 
choice of approaches public engagement , we developed a framework to conceptualize 
potential reasons for the extent and type of public engagement currently undertaken by 
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HTAOs. The framework applies Rowe and Frewer’s broad engagement types (Rowe & 
Frewer 2005) (Figure 1). It also borrows the matrix concept developed by Robinson (2003), 
based on the IAP2 Spectrum (International Association for Public Participation (IAP2) 1999), 
that acknowledges the external factors of complexity and impact and adds the internal 
factors:- transparency and opportunities for involvement in governance in the HTA process 
and time and resource constraints of the HTAO. The framework suggests that each of these 
factors exists along a spectrum or continuum and varies depending on the question.  
 
Figure 1: Simplified process showing the development of the conceptual framework of factors 
influencing public engagement choice  
 
 
Application of the framework   
The upper quadrants of the framework identify the types of public engagement that might 
be most appropriate for technologies where the complexity of the decision is relatively low, 
and where there are already good opportunities for the public to be involved in the HTA 
decision-making process. Engagement options in these situations vary from information 
provision to targeted consultation depending upon the time and resources available to the 
HTAO and the likely impact of the decision. The lower quadrants indicate the types of public 
engagement that might be appropriate for more complex assessments or ones where there 
are limited opportunities for public involvement in the HTA process. Similar to the upper 
quadrants, decisions about public engagement methods would also vary from left to right 
depending upon time and resources and the perceived impact of the decision.  An example 
of an HTA in the lower quadrants is the 2009 assessment of colorectal cancer screening tests 
by the Ontario Health Technology Advisory Committee (OHTAC) (Medical Advisory 
Secretariart 2009). As previously mentioned, screening is often considered to be complex 
and of high impact. A public representative was not part of the OHTAC and so the 
Committee drew upon both an evidence report (Ontario Health Technology Advisory 
Committee 2009) and the views expressed by the Citizens Reference Panel of Health 
Technologies. 
In many circumstances the key factors will cross opposing quadrants. A likely scenario is 
where there is a more complex HTA (due to uncertainties in the evidence) with potential for 
high impact, the HTAO has limited time and resources but the HTAO has put in place some 
opportunities for engagement at the governance level. In these circumstances the HTAO 
must make a trade-off between the factors. A recent example of such a scenario is that of 
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ipilimumab, reviewed by the Pharmaceutical Benefits Advisory Committee (PBAC) in 
Australia (PBAC 2012). This was a highly complex HTA of high impact, but subject to tight 
deadlines. Opportunities for involvement in governance were available (consumer 
representative on committee) as well as targeted consultation (solicited patient stories). 
However in Australia timeliness has often taken precedence over extended public 
consultation (Department of Health and Ageing 2009). In such circumstances, the HTAO 
takes a risk: that the final decision does not cause public dissatisfaction and erosion of 
confidence and trust in the process leading to the public engaging with the media (Street et 
al. 2011) in the hope of reopening the dialogue with the HTAO (Peoplepledge 2011) and 
policy makers.   
Discussion 
At the moment judgments regarding whom and when to engage, and the method of 
engagement are dictated by the particular health care organization. There is very little 
research published identifying the factors that influence HTAOs choice of engagement 
method, so it is difficult for agencies to place their decisions in a broader context or learn 
from others. In particular, there is little information on which HTAOs can draw with respect 
to the ways in which internal pressures such as time and resources or their own 
organizational culture may influence their choice of public engagement process. According 
to some authors, public engagement in health care suffers from limited conceptualization 
and a lack of evidence on the most effective method to engage the public  (Christiaens et al. 
2013;Litva et al. 2002) (Haywood et al. 2014). However these issues are currently receiving 
greater attention (OHTAC Public Engagement Subcommittee 2015) with some significant 
efforts to integrate evaluation into public engagement in HTA decision-making (Dipankui et 
al. 2015) and reflect on potential barriers and enablers.  
HTAOs will also need to demonstrate a genuine commitment to public engagement. 
Engagement that is perceived to be token, and/or undertaken to give legitimacy to a 
decision already made, can erode trust in the process. There are some reports that trust in 
the health care system has been slowing declining (Gille, Smith and Mayes, 2014). With the 
increasing focus on developing patient centered care, improvements have been observed in 
attitudes towards engagement (Forsyth et al 2016)-  however this needs to be embedded 
within organizational structures that promote transparency and inclusiveness. HTAOs 
should also take note of studies that are focused on asking what the public want in relation 
to engagement (Wortley et al 2015) to inform discussions as to whether and how 
engagement should take place within an HTAO. 
Our framework does not suggest a hierarchy of effectiveness of engagement methods; 
indeed research on the comparative effectiveness of the different types of engagement and 
the use in different ‘publics is lacking. (Mitton, Smith, Peacock, Evoy, & Abelson 2009; 
OMara-Eves et al. 2013). A Cochrane review of consumer involvement in healthcare policy 
(Nilsen, Myrhaug, Johansen, Oliver, & Oxman 2006) identified one trial where two 
deliberative techniques were compared to a consultative approach (Abelson et al. 2003a). 
No definitive conclusions could be reached due to methodological limitations (Nilsen, 
Myrhaug, Johansen, Oliver, & Oxman 2006). The randomized trial conducted by the AHRQ 
EHCP cited earlier (Carman KL et al. 2013b) found each deliberative method was effective in 
increasing knowledge; however community deliberation and citizens’ panel techniques may 
be more appropriate for more complex topics.  Other similar research projects are ongoing 
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(Gagnon et al. 2012) and our understanding of strengths and weaknesses of different public 
engagement approaches is likely to improve with the increasing interest in patient centered 
policymaking and practice (Methodology Committee of the Patient-Centered Outcomes 
Research Institute (PCORI 2012)). This also applies to our understanding of the use of 
multiple publics (Martin 2012). 
It is increasingly recognized that traditional methods of public engagement may become 
increasingly ineffective as HTAs become more complex and publics simultaneously become 
more informed and demand more representation (Abelson, Forest, Eyles, Smith, Martin, & 
Gauvin 2003b; Street et al. 2008). There has, for example, been growing interest in recent 
years in applying novel quantitative methods to incorporating the values of patients and the 
community in HTA decision-making.  This includes models of value based pricing (Garner 
2010;Linley and Hughes 2012) as well as the use of multi-criteria decision making (MCDA) 
and discrete choice experiments (Adunlin et al. 2014;Danner et al. 2011). Such approaches, 
if implemented in HTA, could see public engagement focused on developing relative weights 
for criteria around the complexity and impact of an HTA (Linley & Hughes 2013). This could 
potentially lead to more transparent and systematic public engagement processes (Dowie et 
al. 2015;Tony et al. 2011). It could also capture many of the benefits of directly 
incorporating preferences and social values into decision-making whilst avoiding the time 
delay and cost associated with undertaking additional public engagement.  
Given these complexities, it will be crucial to determine what factors are important to the 
relevant ‘publics’ in determining the type of engagement undertaken by HTAOs.  It may be 
that in some circumstances the public are happy not to be involved in decision making 
(Litva, Coast, Donovan, Eyles, Shepherd, Tacchi, Abelson, & Morgan 2002;Lomas 1997) or 
that they have an unexpected preference regarding the most appropriate mode of 
engagement. Few published studies are available on this topic (Wortley et al 2016b). While 
this paper touches on some of these issues - it is from an organizational perspective and 
relies on interpretive analysis. Further studies, analysis and evaluation are needed in this 
area to determine public preferences around engagement as well as the features that 
facilitate public engagement in decision-making (Emery et al 2105).  Having this information 
will assist us in choosing engagement methods, improving transparency and thereby 
effectively integrating social values into the HTA decision-making process. 
Conclusions 
There is no universal or ideal approach to public engagement into HTA processes. While 
multiple methods exist, HTAOs have tended to focus on a limited range of approaches. Four 
main drivers appear to guide the choice of engagement type used by contemporary HTAOs. 
The dictates of these factors are rarely explicitly acknowledged by HTAOs. Rather, 
engagement is simply framed as an imperative with little consideration given to whether 
engagement is desired by the public, which publics should be included, whether the chosen 
approach is appropriate to achieve the intended outcome, or how engagement should be 
tailored for particular technologies. This is an unsatisfactory state of affairs, and there is a 
need for greater understanding of what methods ‘work’ best in particular situations, 
development of new methods of engagement to account for increasing complexity, and 
greater understanding of how the various ‘publics’ themselves want to participate in HTA.  
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